|
|
93 Red River
Austin, TX 78701 USA
phone:512-637-2076
fax:
|
|
| Symbol |
N/A |
| Exchange |
N/A |
| Founded |
2006 |
| Employees |
45 |
|
|
| www.spinesmithusa.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| SpineSmith Partners, LLC is building a proprietary, high margin business commercializing the use of autologous adult stem cells ("ASCs") and implants optimized for use with stem cells in spine surgery. |
|
| Management |
| Kevin Dunworth (CEO/Founder); Steve Melchiode (President); Mike Gluk (COO/CFO); Dr. James Poser (VP-Regenerative Medicine); Brian Burkinshaw (VP-Engineering); Dr. Ted Sand (VP Cellular Therapies) |
| |
|
|
|
|
|
|
|
| Keywords |
| Adult Stem Cell, Spinal Fusion, Cervical Fusion, Lumbar Fusion, Biologics, Orthopedics, Neurology |
|
|
|
| Description |
|
SpineSmith delivers ASCs at the point of care in the operating room via professional service delivery teams and technology capable of consistently, reliably providing appropriate cell preparations. Additionally, the company designs and markets cervical and lumbar spinal implants that are protected by 16 patent applications. Future product development efforts are focused on development of a licensed, proprietary, bone graft material and implants optimized for cellular therapies. |
|
| Products / Services |
VisuALIF, Cequence, Cimplicity, Cynch, ART 21-MarrowXpress, ART 21-Res-Q
|
|
| Market / Customers |
SpineSmith competes in four primary markets - fusion growth factors, bone grafting materials, cervical implants and lumbar implants.
SpineSmith's customer base is comprised of hospitals, orthopedic surgeons and neurosurgeons.
|
|
| Funding |
| SpineSmith completed a $1.45 million round of equity financing in 2006. |
|
| Status |
| SpineSmith is seeking $5 million in growth capital to fund the completion of its product development program and expand its commercial operations. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members